Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: A potent tool for identification and characterization of topoisomerase II-targeting antitumour agents

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 5, 1998, Pages 345-356

  Van Hille, Benoît ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antitumour drugs; Bisdioxopiperazine compounds; Human; ICRF 193; Topoisomerase II; Yeast

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; 2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; COLCHICINE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DISTAMYCIN A; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTICINE; EPIPODOPHYLLOTOXIN; ETOPOSIDE; GENISTEIN; NAVELBINE; PODOPHYLLOTOXIN; RAZOXANE; TOP 53; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG CLASSIFICATION; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; YEAST CELL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL MEMBRANE PERMEABILITY; CULTURE MEDIA; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; PLASMIDS; SACCHAROMYCES CEREVISIAE; STRUCTURE-ACTIVITY RELATIONSHIP; VINBLASTINE;

EID: 0031684652     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050828     Document Type: Article

References (35)

1. Adachi N, Kobayashi M, Koyama H (1997) Analysis of mouse DNA topoisomerase IIα: regulation of gene expression and production of mutant embryonic stem cells. Poster no. 28, VIIIth Conference on DNA Topoisomerases in Therapy, Amsterdam
2. Austin CA, Marsh KL, Wasseman RA, Willmore E, Sayer PJ, Wang JC, Fisher LM (1995) Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 270: 15739
3. Ausubel FM, Brent R, Kingston RE, More DD, Seidman JG, Smith JA, Struhl K (1995) Current protocols in molecular biology. Current protocols (eds), Wiley, Boston, p 1305
4. Beck WT, Danks MK, Wolverton JS, Kim R, Chen M (1993) Drug resistance associated with altered DNA topoisomerase II. Adv Enzyme Regul 33: 113
5. Bjornsti MA, Benedetti P, Viglianti G, Wang JC (1989) Expression of human topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumour drug camptothecin. Cancer Res 49: 6318
6. Budman DR (1996) Early studies of etoposide phosphate, a water soluble prodrug. Semin Oncol 23: 8
7. Cummings J, Smyth JF (1993) DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 4: 533
8. Eng WK, Faucette L, Johnson RK, Sternglanz R (1988) Evidence that DNA toposiomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755
9. Hasinoff BB, Kuschak TI, Creighton AM, Fattman CL, Allan WP, Thampatty P, Yalowich JC (1997) Characterization of a Chinese Hamster Ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol 53: 1843
10. Hays SL, Firmenich AA, Berg P (1995) Complex formation in yeast double-strand break repair: participation of Rad51, Rad52, Rad55, and Rad57 proteins. Proc Natl Acad Sci USA 92: 6925
11. Hille B van, Lohri A, Reuter A, Herrmann R (1996) Assessment of drug-induced dysregulations among seven resistance-associated genes in human tumour cell lines. Anticancer Res 16: 3531
12. Hsiang Y-H, Liu LF (1988) Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722
13. Hsiung Y, Jannatipour M, Rose A, McMahon J, Duncan D, Nitiss JL (1996) Functional expression of human topoisomerase IIα in yeast: mutations at amino acids 450 or 803 of topoisomerase IIα result in enzymes that can confer resistance to anti-topoisomerase agents. Cancer Res 56: 91
14. Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, Andoh T (1995) DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae. Cancer Res 55: 2299
15. Jensen S, Andersen AH, Kjeldsen E, Biersack H, Olsen EH, Andersen TB, Westergaard O, Jakobsen BK (1996) Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae. Mol Cell Biol 16: 3866
16. Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K (1991) Expression of mdr1, GST-π and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11: 429
17. Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK, Hertzberg RP (1991) Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumour activity. J Med Chem 34: 98
18. Lefevre D, Riou JF, Ahomadegre JC, Zhou D, Bernard J, Riou G (1991) Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Biochem Pharmacol 41: 1967
19. Liu LF (1989) DNA topoisomerase poisons as antitumour drugs. Annu Rev Biochem 58: 351
20. Liu Y-X, Hsiung Y, Jannatipour M, Yeh Y, Nitiss JC (1994) Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new topoisomerase II mutants selected for resistance to etoposide. Cancer Res 54: 2943
21. Meczes EL, Marsh KL, Fisher LM, Rogers MP, Austin CA (1997) Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct that allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 39: 367
22. Muller MT, Helal K, Soisson S, Spitzner JR (1989) A rapid and quantitative assay for eukaryotic topoisomerase II. Nucleic Acids Res 17: 9499
23. Nitiss JL (1994) Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother Pharmacol 34: S6
24. Nitiss JL, Beck WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer 32A: 958
25. Nitiss J, Wang JC (1988) DNA topoisomerase-targeting anti-tumour drugs can be studied in yeast. Proc Natl Acad Scei USA 85: 7501
26. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast overexpressing DNA topoisomerase II. Cancer Res 52: 4467
27. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16-213) current status of an active anticancer drug. N Engl J Med 312: 692
28. Osheroff N (1989) Biochemical basis for the interactions of type 1 and type II topoisomerases with DNA. Pharmacol Ther 41: 223
29. Roca J, Ishida R, Berger JM, Andoh T, Wang JC (1994) Antitumour bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91: 1781
30. Sehested M, Jensen PB (1996) Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol 51: 879
31. Tanahe K, Ikegami Y, Ishida R, Andoh T (1991) Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 41: 4903
32. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC (1988) Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21 22. Proc Natl Acad Sci USA 85: 7177
33. Utsugi T, Herzog CE, Fan D (1995) Topoisomerases in multidrug resistance. In: Kellen JA (ed) Alternative mechanisms of multidrug resistance in cancer. Birkhauser, p 95
34. Wasserman RA, Austin CA, Fisher LM, Wang JC (1993) Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res 53: 3591
35. Worland ST, Wang JC (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from yeast Saccharomyces cerevisiae. J Biol Chem 264: 4412